Format

Send to

Choose Destination
Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1275-9.

Paclitaxel and concurrent radiation for locally advanced pancreatic cancer.

Author information

1
The Brown University Oncology Group, Providence, RI 02906, USA.

Abstract

PURPOSE:

To determine the activity and toxicity of paclitaxel and concurrent radiation for pancreatic cancer.

METHODS AND MATERIALS:

Forty-four patients with locally unresectable pancreatic cancer were studied. Patients received paclitaxel, 50 mg/m(2) by 3 h i.v. (IV) infusion, weekly, on Days 1, 8, 15, 22 and 29. Radiation was administered concurrently to a total dose of 50.4 Gy, in 1.80 Gy fractions, for 28 treatments.

RESULTS:

Nausea and vomiting were the most common toxicities, Grade 3 in five patients (12%). Two patients (5%) had Grade 4 hypersensitivity reactions to their first dose of paclitaxel. Of 42 evaluable patients, the overall response rate was 26%. The median survival was 8 months, and the 1-year survival was 30%.

CONCLUSION:

Concurrent paclitaxel and radiation demonstrate local-regional activity in pancreatic cancer. Future investigations combining paclitaxel with other local-regional and systemic treatments are warranted.

PMID:
11286834
DOI:
10.1016/s0360-3016(00)01527-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center